Summer 2026 - Informatics and Predictive Sciences Internship at Bristol-Myers Squibb

Madison, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Enrolled in a PhD program in bioinformatics, computational biology, or a quantitative discipline (preferred)
Demonstrated scientific curiosity and interest in translational research and drug development
Strong programming skills in Python, including use of PyTorch and standard data science libraries
Strong interest in gaining hands-on experience with deep learning models
Experience in data wrangling, statistical analysis, and data visualization
Ability to research, critically evaluate, and synthesize scientific literature
Ability to work independently and as a member of a broader computational team
Authorized to work in the US both at the time of hire and for the duration of employment (no immigration or visa sponsorship available)

Responsibilities

Conduct literature reviews and benchmark current state-of-the-art cross-modality data translation methods
Implement and customize generative models tailored to clinical trial datasets with minimal feature overlap
Evaluate translation performance using cluster robustness, correlation, and other relevant metrics
Explore and prototype supervised extensions, including clinical outcome integration and uncertainty quantification
Document code, create reproducible analysis scripts, and contribute to packaging methods for future deployment and cross-team collaboration

Skills

Machine Learning

Variational Autoencoder

VAE

Generative Models

Clinical Trial Data

Pharmacometrics

Literature Review

Cluster Analysis

Correlation Metrics

Uncertainty Quantification

Python

Reproducible Analysis

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free